Rosenbaum, E., Chugh, R., Ryan, C. W., Agulnik, M., Milhem, M. M., George, S., Jones, R. L., Chmielowski, B., Van Tine, B. A., Tawbi, H., Elias, A. D., Read, W. L., Budd, G. T., Qin, L.-X., Rodler, E. T., Hirman, J., Weiden, P., Bennett, C. M., Livingston, P. O., … Carvajal, R. D. (2022). A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. European Journal of Cancer, 176, 155–163. https://doi.org/10.1016/j.ejca.2022.09.003